Archive · 19 Sep 2025
Ajanta Pharma Initiated with 'Buy' Rating, Target ₹3,200
Ajanta Pharma, a pharmaceutical company, has been given a 'Buy' rating by analysts.
They expect the company's revenue to grow by 13% each year from 2025 to 2028.
This growth is due to their focus on branded medicines, expansion into new areas of treatment, and scaling up in the US generic market.
The company makes medicines for several health problems, especially chronic ones.
They also entered two new areas and acquired three brands in FY25.
Analysts expect good profits with healthy returns.
Coverage initiated on Ajanta Pharma with a 'Buy' rating and target price of ₹3,200.
Branded generics contributed 74% to total revenue in FY25.
Company expects a 13% revenue CAGR over FY25-28E.
Focused on high-growth specialty therapies including cardiac, ophthal, derma, and pain management.
Expected EBITDA/PAT CAGR of 17/16% over FY25-28E.
- Who
- Ajanta Pharma
- What
- Coverage initiated with a 'Buy' rating.
- When
- As of September 19, 2025
- Where
- India, Asia, Africa, and US generics market
- Why
- Driven by branded generics and expansion into new therapies.
- Rating
- Buy
- Target Price
- ₹3,200
- CMP
- ₹2,545.80
- FY25 Revenue from Branded Generics
- 74%
- FY22-25 CAGR
- 12.5%
- Expected FY25-28E Revenue CAGR
- 13%
- Domestic Formulations Contribution (FY25)
- 32%